Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.78 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.78 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | ADORA2B | P29275 | 10/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17486883 | 0.89 | LMNA (0.76) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| Proxyphylline SCHEMBL35569 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL20011104 | 0.88 | LMNA (0.62) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL11033822 | 0.88 | PDE1A (0.73) | LMNASMN1; SMN2POLBADORA2B | |
| (S)-Proxyphylline SCHEMBL35570 | 0.88 | LMNA (1.00) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL18399526 | 0.86 | ADORA2B (0.68) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL13944619 | 0.86 | LMNA (0.81) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL10859640 | 0.85 | LMNA (0.80) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL11750405 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2POLBADORA2BMAPT | |
| SCHEMBL683878 | 0.85 | LMNA (0.80) | LMNASMN1; SMN2POLBADORA2BMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 389 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LTD (AU) | 2025-01-16 | — | — | US | claimed |
| WO-2024189434-A1 | USE OF NADOLOL TO TREAT PULMONARY SYMPTOMS ASSOCIATED WITH INFECTIONS WITH SARS-CoV-2 | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2024-09-19 | — | — | WO | claimed |
| CN-117683713-A | In vitro preparation of T lymphocytes and NK cells using human pluripotent stem cells | 北京大学 | 2024-03-12 | — | — | CN | claimed |
| EP-4304717-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | Chronic Airway Therapeutics Limited (AU) | 2024-01-17 | — | — | EP | claimed |
| CN-117174554-A | Quasi-optical mode converter for terahertz gyrotron traveling wave tube with single confocal structure | 电子科技大学 | 2023-12-05 | — | — | CN | claimed |
| EP-3870236-B1 | NANOPARTICLE ENCAPSULATION TO TARGET G PROTEIN-COUPLED RECEPTORS IN ENDOSOMES | TAKEDA PHARMACEUTICALS CO (JP) | 2023-08-09 | — | — | EP | claimed |
| CN-116376822-A | In vitro preparation of T lymphocytes by using human pluripotent stem cells | 北京大学 | 2023-07-04 | — | — | CN | claimed |
| CN-112376074-B | Electrochemical fluorination external circulation efficient electrolysis system | 中船(邯郸)派瑞特种气体股份有限公司 | 2022-11-25 | — | — | CN | claimed |
| CN-217732699-U | Process device capable of recovering sulfur steam in sulfur storage tank of carbon disulfide device | 辽宁瑞兴化学有限公司 | 2022-11-04 | — | — | CN | claimed |
| WO-2022192252-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | CHRONIC AIRWAY THERAPEUTICS LIMITED (AU) | 2022-09-15 | — | — | WO | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1684764-A2 | METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS AND FOR SCREENING FOR AGENTS ACTING AS INVERSE AGONISTS | Inverseon, Inc. (US) | 2006-08-02 | — | — | EP | claimed |
| EP-1677778-A2 | METHOD OF TREATING AIRWAY DISEASES WITH BETA-ADRENERGIC INVERSE AGONISTS | Inverseon, Inc. (US) | 2006-07-12 | — | — | EP | claimed |
| WO-2006013205-A1 | NEUROKININ-1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CONDITIONS RESPONSIVE TO TESTOSTERONE ELEVATION | SOLVAY PHARMACEUTICALS B.V. (NL) | 2006-02-09 | — | — | WO | claimed |
| US-20060030556-A1 | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency | SOLVAY PHARMACEUTICALS B.V. | 2006-02-09 | — | — | US | claimed |
| WO-2005035731-A2 | METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS AND FOR SCREENING FOR AGENTS ACTING AS INVERSE AGONISTS | INVERSEON, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| WO-2005034871-A2 | METHODS FOR TREATING DISEASES AND CONDITIONS WITH INVERSE AGONISTS | INVERSEON, INC. (US) | 2005-04-21 | — | — | WO | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250017878-A1 | USE OF NADOLOL TO TREAT CHRONIC OBSTRUCTIVE PULMONARY DISEASE BY BLOCKAGE OF THE ARRESTIN-2 PATHWAY | ARRB1, ADRB2, ADRB1 | LMNA 2136/4885SMN1; SMN2 3453/4885POLB 310/4885 |
| US-20060030556-A1 | Neurokinin-1 receptor antagonists for the treatment of conditions responsive to testosterone elevation, including testosterone deficiency | GNRHR, TACR2, SHBG | LMNA 3509/4885SMN1; SMN2 3217/4885POLB 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.